Moreover, anti-PD-1 monoclonal antibodies not only act at the primary tumor site but also display additional activity in the periphery (48–50), particularly in the TDLNs (30, 51, 52), promoting the magnitude and quality of tumor antigen-specific CD8+ T cell responses in TDLNs (33). This evidence concerns the gene CD8A and neoplasm.